DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548 | Completed Phase 3 Results FDA Drug

• 1 other identifier: DARE-BV1-001
• Study Type: interventional
• Target: 307
• Locations: 1 country
• Sites: 10

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC Universal Placebo Gel) (QD × 1 day) for the treatment of bacterial vaginosis. Patients will be evaluated at three time points: a Day 1 Screening/Randomization visit, a Day 7-14 Interim Assessment visit, and a Day 21 - 30 Test of Cure \[TOC\] visit). Patients who discontinue prematurely from the study will receive a safety follow-up phone call between Day 21-30. The total study duration will be approximately one month for each individual patient.

Conditions

Bacterial Vaginosis

Outcome Measures

Primary Outcomes (1)

• Number of Patients With Clinical Cure at the TOC Visit (Day 21-30).

  Clinical cure is defined as: * Resolution of the abnormal vaginal discharge associated with BV; * Negative 10% KOH "whiff test;" and * Clue cells \< 20% of the total epithelial cells in the saline wet mount.

  Visit 3 Day 21-30 post randomization

Secondary Outcomes (5)

• Number of Patients With Clinical Cure at the Interim Assessment Visit (Day 7-14).

  Visit 2 Day 7-14 post randomization

• Number of Patients With Bacteriological Cure at the TOC Visit (Day 21-30).

  Visit 3 Day 21-30 post randomization

• Number of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14

  Visit 2, Days 7-14 post randomization

• Number of Patients With Therapeutic Cure at the TOC Visit (Day 21-30).

  Visit 3 Day 21-30 post randomization

• Number of Patients With Therapeutic Cure at the Interim Assessment Visit (Day 7-14).

  Visit 2 Day 7-14 post randomization

Other Outcomes (6)

• Number of Patients With Clinical Cure at the Test of Cure Visit (21-30)

  Visit 3, Days 21-30 post randomization

• Number of Patients With Clinical Cure at Interim Assessment Visit, Days 7-14, PP Population

  Visit 2, Days 7-14 post randomization

• Number of Patients With Bacteriological Cure at Test of Cure Visit, Days 21-30, PP Population

  Visit 3, Days 21-30 post randomization

Study Arms (2)

Clindamycin phosphate vaginal gel, 2%

EXPERIMENTAL

Drug: DARE-BV1clindamycin phosphate vaginal gel, 2%

Placebo vaginal gel (Universal HEC Placebo Gel)

PLACEBO COMPARATOR

Drug: DARE-BV1clindamycin phosphate vaginal gel, 2%

Interventions

DARE-BV1clindamycin phosphate vaginal gel, 2% DRUG

One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.

Also known as: Placebo vaginal gel (HEC Universal Placebo Gel)

Clindamycin phosphate vaginal gel, 2%; Placebo vaginal gel (Universal HEC Placebo Gel)

Eligibility Criteria

• Age: 12 Years+
• Gender Eligibility Details: Female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must provide written informed consent prior to any study-related procedures being performed. Patients from 12 through 17 years old may participate where permitted by applicable local regulations and Institutional Review Board (IRB) approval and with appropriate documentation of consent from the parent(s)/guardian(s) and assent from the patient.
• Participants must have a clinical diagnosis of bacterial vaginosis, defined as having all of the following:
• Off-white (milky or gray), thin, homogeneous discharge with minimal or absent pruritus and inflammation of the vulva and vagina
• The presence of clue cells \> 20% of the total epithelial cells on microscopic examination of the saline wet mount
• Vaginal secretion pH of \> 4.5
• A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH (i.e., a positive "whiff test")
• Participants must be females ≥ 12 years of age with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
• Participants of childbearing potential must have a negative urine pregnancy test result at screening, should use adequate birth control after the first seven days of treatment if engaging in heterosexual intercourse, and should not plan on becoming pregnant for the duration of the study. Acceptable forms of birth control include oral contraceptives (the pill), intrauterine devices (IUDs), contraceptive implants under the skin, patches or injections, and non-polyurethane condoms (e.g., latex, polyisoprene) with or without spermicide. Patients in monogamous relationships with vasectomized males may also participate. Abstinence may be allowed, but requires Medical Monitor (or designee) approval prior to randomization. Oral or transdermal hormonal contraceptives must be in use for one full cycle (e.g., four to eight weeks) prior to study drug application. Injectable or implanted contraceptives (e.g., Depo-Provera, Nexplanon, or hormonal IUD) must be injected/inserted at least seven days prior to study drug application. Participants who are not of childbearing potential, as defined below, must also have a negative urine pregnancy test prior to randomization:
• Postmenopausal for at least one year prior to the Entry Visit (Visit 1) (defined as amenorrheic for more than one continuous year), or
• Surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) at least 6 months before first dose, or
• Non-surgical permanent sterilization procedure at least 3 months prior to first dose.
• Participants must be willing to refrain from the use of all intra-vaginal products (e.g., douches, feminine deodorant sprays, condoms, spermicides, vaginal moisturizers and lubricants, tampons, vaginal birth control rings \[e.g., NuvaRing®\], and diaphragms) through the first 7 days at a minimum, and ideally through Visit 3 (Day 21-30) or Study Exit/Early Discontinuation.
• Participants must be able to read, write, and understand English.

You may not qualify if:

• Patients with active vulvovaginitis or other active infectious causes of cervicitis, vaginitis, or vulvitis (e.g., candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, or genital lesions or ulcers consistent with human papillomavirus, active Herpes simplex, syphilis, chancroid, etc.).
• Potential participants who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study as described above.
• Patients with a vaginal, vulvar, or genitourinary condition that, according to the Investigator's judgement, may confound the interpretation of clinical response.
• Patients with a history of regional enteritis, ulcerative colitis, or a history of C. difficile associated diarrhea.
• Patients with known current drug or alcohol abuse that could impact study compliance.
• Patients currently receiving or who have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days of the Screening/Randomization visit.
• Patients who have used any other investigational product within 30 days of the screening/randomization visit.
• Patients who will undergo evaluation or treatment during the study for abnormal cytology and/or findings from high risk HPV testing and/or Pap test finding.
• Patients with known sensitivity to clindamycin phosphate or other lincosamides or any of the inactive ingredients in the study drug.
• Patients with a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the patient inappropriate for entry into the trial.

Sponsors & Collaborators

• Daré Bioscience, Inc.: lead

Study Sites (10)

Vision Clinical Research-Tuscon

Tucson, Arizona, 85712, United States

Location

Downtown Women's Health Care

Denver, Colorado, 80209, United States

Location

New Age Medical Research Corporation

Miami, Florida, 33186, United States

Location

Precision Clinical Research, LLC

Sunrise, Florida, 33351, United States

Location

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, 33409, United States

Location

NuDirections Clinical Research, Inc.

Lawrenceville, Georgia, 30044, United States

Location

Capital Health-Lawrence OB/GYN

Lawrenceville, New Jersey, 08648, United States

Location

The Center for Women's Health & Wellness, LLC

Lawrenceville, New Jersey, 08684, United States

Location

The Jackson Clinic, PA

Jackson, Tennessee, 38305, United States

Location

Eastern Virginia Medical School

Norfolk, Virginia, 23507, United States

Location

Related Publications (2)

• Mauck C, Hillier SL, Gendreau J, Dart C, Wu H, Chavoustie S, Sorkin-Wells V, Nicholson-Uhl CS, Perez B, Jacobs M, Zack N, Friend D. Acceptability of Single-dose Clindamycin Gel for Bacterial Vaginosis: A Randomized Controlled Trial. Clin Ther. 2023 May;45(5):415-425. doi: 10.1016/j.clinthera.2023.04.001. Epub 2023 Apr 23.

  PMID: 37098453 DERIVED

• Mauck C, Hillier SL, Gendreau J, Dart C, Chavoustie S, Sorkin-Wells V, Nicholson-Uhl C, Perez B, Jacobs M, Zack N, Friend D. Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2022 Jun 1;139(6):1092-1102. doi: 10.1097/AOG.0000000000004805. Epub 2022 May 2.

  PMID: 35675606 DERIVED

MeSH Terms

Conditions

Vaginosis, Bacterial

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Vaginitis; Vaginal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Results Point of Contact

• Title: VP, Clinical Operations
• Organization: Dare Bioscience, Inc.

nzack@darebioscience.com

858-926-7655

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: double blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Eligible patients will be randomly assigned to one of the following treatment groups (2:1): DARE- BV1 clindamycin phosphate vaginal gel, 2% (1 dose is 5 g gel = 100 mg clindamycin) QD × 1 day, or placebo vaginal gel (Universal HEC Placebo Gel), 5g, QD × 1 day. Study drug will be applied intravaginally within 1 day of randomization.

Study Record Dates

• First Submitted: April 3, 2020
• First Posted: May 1, 2020
• Study Start: June 16, 2020
• Primary Completion: November 30, 2020
• Study Completion: December 7, 2020
• Last Updated: December 8, 2022
• Results First Posted: July 2, 2021

Record last verified: 2022-12

Locations

US (10)